Decoy Therapeutics Inc.
DCOY · XNASCIK 1615219fmd_1867FXMP2DYEWAQP13W8PKKCHS制造业 · 医药制剂模板: 标准
覆盖范围: 2014年1月01日 至 2026年9月30日，共 50 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | 1 | 2 | 3 | 5 | 2 | 0 | – | – | – |
| 营业成本 | 1 | 1 | 0 | – | – | – | – | – | – | – |
| 毛利润 | 0 | 1 | 2 | – | – | – | – | – | – | – |
| 研发费用 | 20 | 17 | 1 | 4 | 7 | 9 | 16 | 7 | 1 | 0 |
| 营业费用合计 | 41 | 36 | 4 | 12 | 13 | 15 | 32 | 13 | 6 | 13 |
| 营业利润 | (40) | (35) | (2) | (8) | (8) | (13) | (32) | (13) | (6) | (13) |
| 税前利润 | – | – | – | – | – | – | – | – | – | – |
| 所得税费用 | – | – | – | 0 | – | – | – | – | – | 0 |
| 持续经营净利润 | – | – | (2) | (7) | (7) | – | – | – | – | – |
| 净利润 | (39) | (34) | (2) | (7) | (7) | (13) | (32) | (13) | (6) | (13) |
| 归属于普通股股东的净利润 | (39) | (34) | (22) | (7) | (8) | (13) | (32) | (13) | (6) | – |